Latest Lung Cancer News for Patients

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

Deadly, rare lung cancer finds big foe: Patients with little to lose

The San Francisco Business Times recently featured ALCF for the work we are doing, at the request of our patients, to study the ROS1 gene.

Posted by ALCF Staff on February 8th, 2017

New Search Tool to Find Clinical Trials

New lung cancer treatments such as immunotherapy and targeted treatments are being researched in clinical trials every day, and we encourage you to get involved. That’s why we’re proud to announce a new partnership with digital health startup Antidote that will make it easier than ever for you to connect with medical research. Using our… Read More

Posted by ALCF Staff on January 18th, 2017

Partners In Promise 2016

Dear Friends, Lung cancer is personal for the people whose stories you will read in “Partners in Promise.” Many thanks to our “Patient Partners” for sharing their stories and to our many “Donor Partners” whose generosity makes progress possible. After reading about Alex, Lisa, Xiuting and other patients, please consider making a tax-deductible donation by… Read More

Posted by Bonnie J. Addario on December 27th, 2016

Statement by Bonnie J. Addario, Founder and President of the Addario Lung Cancer Foundation, on the 21st Century Cures Act

The signing of the 21st Century Cures Act is a blessing for past, current and future patients everywhere. This monumental legislation is 40 years in the making. In the time since I was diagnosed and ultimately survived lung cancer, I have dedicated the last decade plus of my life to ground-breaking research and prioritizing the… Read More

Posted by Bonnie J. Addario on December 13th, 2016

NFL linebacker, Chris Draft, kicking off Team Draft’s third annual Lung Cancer Survivors Super Bowl Challenge

November is Lung Cancer Awareness Month and former NFL linebacker and international health care advocate, Chris Draft, is marking the occasion by kicking off Team Draft’s third annual Lung Cancer Survivors Super Bowl Challenge. This unique fund raising challenge gives lung cancer survivors the opportunity to raise funds for public awareness and cutting-edge research that… Read More

Posted by ALCF Staff on November 15th, 2016

New Lung Cancer Registry Launched Today

The Bonnie J. Addario Lung Cancer Foundation (ALCF), the American Lung Association (ALA) and AltaVoice (formerly known as PatientCrossroads) today announced the new Lung Cancer Registry. The Registry is a place to gather and store detailed information for patients with lung cancer, which kills more Americans each year than the next three most frequent types… Read More

Posted by ALCF Staff on November 4th, 2016

FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Genentech’s PDL1 drug approved in the second line setting for people “with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.”’s-Cancer-Immunotherapy-TECENTRIQ®-Atezolizumab

Posted by ALCF Staff on October 18th, 2016

Study: An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

This is a Phase 1/2 clinical research study for subjects with advanced malignancies. This study will be conducted in three treatment groups with each treatment having two parts; a dose escalation (Part 1) and an expansion (Part 2). This study is accepting patients with Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia, Myelodysplastic /Myeloproliferative neoplasms… Read More

Posted by ALCF Staff on October 18th, 2016

Study: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies

This is a Phase 1/2 clinical research study in patients with previously treated B-cell malignancies. Examples of eligible B-cell malignancies include: Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma, and chronic lymphocytic leukemia. The primary purpose of this study is to study the safety and tolerability of INCB050465… Read More

Posted by ALCF Staff on October 18th, 2016

About Guneet Walia, PhD

Dr. Guneet Walia is here to serve as your guide through what can feel like an overwhelming amount of information and jargon in lung cancer research. With her extensive background in oncology & drug development in the lab and experience working with cancer patients, she culls through the latest news to bring you the most important developments that can impact you and your disease today. If you have any questions, please don't hesitate to get in touch with Dr. Walia.